Wu C, Feng ML, Jiao TW, Sun MJ. Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer. World J Clin Cases 2022; 10(14): 4368-4379 [PMID: 35663086 DOI: 10.12998/wjcc.v10.i14.4368]
Corresponding Author of This Article
Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscope, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. sunydyy@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Clinical and Translational Research
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 16, 2022; 10(14): 4368-4379 Published online May 16, 2022. doi: 10.12998/wjcc.v10.i14.4368
Clinical and prognostic significance of expression of phosphoglycerate mutase family member 5 and Parkin in advanced colorectal cancer
Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun
Can Wu, Ming-Liang Feng, Tai-Wei Jiao, Ming-Jun Sun, Department of Endoscope, The First Hospital Affiliated to China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Wu C and Sun MJ designed the research study; Feng ML and Jiao TW performed the research; Wu C and Feng ML contributed new reagents and analytic tools; Wu C and Jiao TW analyzed the data and wrote the manuscript; Wu C has received research funding; and all authors have read and approved the final manuscript.
Supported bythe Natural Science Foundation of Liaoning Province, No. 2019-BS-279.
Institutional review board statement: This study was approved by the Institutional Review Board of The First Affiliated Hospital of China Medical University (No. 2021-68-2).
Clinical trial registration statement: This study is registered at clinical hospital center “The First Hospital Affiliated to China Medical University” trial registry. The registration identification number is No. 2021-68-2.
Informed consent statement: Informed consent statement was waived.
Conflict-of-interest statement: There are no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Jun Sun, Doctor, PhD, Chief Physician, Professor, Department of Endoscope, The First Hospital Affiliated to China Medical University, No. 155 Nanjing North Street, Shenyang 110001, Liaoning Province, China. sunydyy@163.com
Received: August 2, 2021 Peer-review started: August 2, 2021 First decision: September 4, 2021 Revised: September 17, 2021 Accepted: March 25, 2022 Article in press: March 25, 2022 Published online: May 16, 2022 Processing time: 283 Days and 16.6 Hours
ARTICLE HIGHLIGHTS
Research background
Phosphoglycerate mutase family member 5 (PGAM5) activates serine/threonine PTEN-induced putative kinase 1/Parkin pathway-mediated mitophagy. However, there are few studies on the clinical and prognostic significance of expression of PGAM5 protein and mitophagy-related protein Parkin in colorectal cancer (CRC) patients.
Research motivation
Both PGAM5 and Parkin protein expression has diagnostic significance for CRC and may become new biomarkers.
Research objectives
To assess the clinical significance of PGAM5 and Parkin proteins, as biomarkers for diagnosis and prognosis of CRC, by studying their expression in advanced CRC tissues and their association with clinicopathological parameters.
Research methods
We used immunohistochemistry to determine the expression of PGAM5 and Parkin in CRC tissues from 100 patients. More than that, we employed western blot to measure PGAM5 and Parkin protein expression in six matched pairs of CRC and adjacent non-tumor tissues.
Research results
We found that both PGAM5 and Parkin protein expression in tumor tissues was significantly higher than that in the adjacent tissues according to immunohistochemical and western blot. What’s more, PGAM5 and Parkin protein levels were significantly positively correlated in advanced CRC tissues. And reduced Parkin protein expression was an independent prognostic factor for overall survival and progression-free survival in CRC patients as evinced by multivariate analysis.
Research conclusions
The expressions of PGAM5 protein and mitophagy-related protein Parkin has diagnostic significance for CRC and may become new biomarkers. Parkin may be a potential marker for the survival of CRC patients.
Research perspectives
Our data provide a promising foundation for increasing the accuracy of clinical judgment and improving the continued development of cancer treatment and personalized treatment strategies for CRC.
